Compare Moderna, Inc. (MRNA) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs United Microelectronics Corp — how do they compare? Moderna, Inc. trades at $137.54 (market cap $56.02B), while United Microelectronics Corp trades at $22.22 (market cap $54.48B). The key difference: Moderna, Inc. and United Microelectronics Corp are close in size by market cap, and United Microelectronics Corp pays a 1.84% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | UMC | |
|---|---|---|
Market Cap | $56.02B | $54.48B |
Sector | Health | Technology |
52-Week High | $174.38 | $28.02 |
52-Week Low | $22.36 | $6.76 |
Enterprise Value | $52.17B | $51.52B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
UMC trades at $21.82, up 5.06% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.54 versus $0.16 expected, and announced a $0.41 dividend payable in August 2026. Revenue trends show recovery, with 2026 projections at $250.7B and net income margin improving to 32.75%.
Outlook is positive due to earnings momentum and AI expansion plans, but risks include competitive pressures and volatility from AI spending concerns. Analyst consensus is mixed with 27% buy ratings, suggesting cautious optimism amid high valuation multiples like P/E of 20.96.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
